Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...
Ausführliche Beschreibung
Autor*in: |
Vittorio Fusco [verfasserIn] Giuseppina Campisi [verfasserIn] Paul de Boissieu [verfasserIn] Federico Monaco [verfasserIn] Anna Baraldi [verfasserIn] Gianmauro Numico [verfasserIn] Alberto Bedogni [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2018 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Dentistry Journal - MDPI AG, 2013, 6(2018), 3, p 42 |
---|---|
Übergeordnetes Werk: |
volume:6 ; year:2018 ; number:3, p 42 |
Links: |
---|
DOI / URN: |
10.3390/dj6030042 |
---|
Katalog-ID: |
DOAJ029722985 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ029722985 | ||
003 | DE-627 | ||
005 | 20230307140515.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/dj6030042 |2 doi | |
035 | |a (DE-627)DOAJ029722985 | ||
035 | |a (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RK1-715 | |
100 | 0 | |a Vittorio Fusco |e verfasserin |4 aut | |
245 | 1 | 0 | |a Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. | ||
650 | 4 | |a osteonecrosis of the jaw | |
650 | 4 | |a ONJ | |
650 | 4 | |a osteonecrosis | |
650 | 4 | |a jaw | |
650 | 4 | |a medication-related osteonecrosis of the jaw | |
650 | 4 | |a MRONJ | |
650 | 4 | |a multiple myeloma | |
650 | 4 | |a denosumab | |
650 | 4 | |a zoledronic acid | |
653 | 0 | |a Dentistry | |
700 | 0 | |a Giuseppina Campisi |e verfasserin |4 aut | |
700 | 0 | |a Paul de Boissieu |e verfasserin |4 aut | |
700 | 0 | |a Federico Monaco |e verfasserin |4 aut | |
700 | 0 | |a Anna Baraldi |e verfasserin |4 aut | |
700 | 0 | |a Gianmauro Numico |e verfasserin |4 aut | |
700 | 0 | |a Alberto Bedogni |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Dentistry Journal |d MDPI AG, 2013 |g 6(2018), 3, p 42 |w (DE-627)726120650 |w (DE-600)2681351-8 |x 23046767 |7 nnns |
773 | 1 | 8 | |g volume:6 |g year:2018 |g number:3, p 42 |
856 | 4 | 0 | |u https://doi.org/10.3390/dj6030042 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e |z kostenfrei |
856 | 4 | 0 | |u http://www.mdpi.com/2304-6767/6/3/42 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2304-6767 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 6 |j 2018 |e 3, p 42 |
author_variant |
v f vf g c gc p d b pdb f m fm a b ab g n gn a b ab |
---|---|
matchkey_str |
article:23046767:2018----::sencoioteaimeoaainseevndnsmbroernccdomnopvtlrabr |
hierarchy_sort_str |
2018 |
callnumber-subject-code |
RK |
publishDate |
2018 |
allfields |
10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42 |
spelling |
10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42 |
allfields_unstemmed |
10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42 |
allfieldsGer |
10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42 |
allfieldsSound |
10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42 |
language |
English |
source |
In Dentistry Journal 6(2018), 3, p 42 volume:6 year:2018 number:3, p 42 |
sourceStr |
In Dentistry Journal 6(2018), 3, p 42 volume:6 year:2018 number:3, p 42 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry |
isfreeaccess_bool |
true |
container_title |
Dentistry Journal |
authorswithroles_txt_mv |
Vittorio Fusco @@aut@@ Giuseppina Campisi @@aut@@ Paul de Boissieu @@aut@@ Federico Monaco @@aut@@ Anna Baraldi @@aut@@ Gianmauro Numico @@aut@@ Alberto Bedogni @@aut@@ |
publishDateDaySort_date |
2018-01-01T00:00:00Z |
hierarchy_top_id |
726120650 |
id |
DOAJ029722985 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029722985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307140515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/dj6030042</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029722985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vittorio Fusco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medication-related osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MRONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple myeloma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">denosumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">zoledronic acid</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppina Campisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul de Boissieu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federico Monaco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Baraldi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianmauro Numico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Bedogni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Dentistry Journal</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">6(2018), 3, p 42</subfield><subfield code="w">(DE-627)726120650</subfield><subfield code="w">(DE-600)2681351-8</subfield><subfield code="x">23046767</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3, p 42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/dj6030042</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.mdpi.com/2304-6767/6/3/42</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2304-6767</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2018</subfield><subfield code="e">3, p 42</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Vittorio Fusco |
spellingShingle |
Vittorio Fusco misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology |
authorStr |
Vittorio Fusco |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)726120650 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RK1-715 |
illustrated |
Not Illustrated |
issn |
23046767 |
topic_title |
RK1-715 Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid |
topic |
misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry |
topic_unstemmed |
misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry |
topic_browse |
misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Dentistry Journal |
hierarchy_parent_id |
726120650 |
hierarchy_top_title |
Dentistry Journal |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)726120650 (DE-600)2681351-8 |
title |
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology |
ctrlnum |
(DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e |
title_full |
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology |
author_sort |
Vittorio Fusco |
journal |
Dentistry Journal |
journalStr |
Dentistry Journal |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2018 |
contenttype_str_mv |
txt |
author_browse |
Vittorio Fusco Giuseppina Campisi Paul de Boissieu Federico Monaco Anna Baraldi Gianmauro Numico Alberto Bedogni |
container_volume |
6 |
class |
RK1-715 |
format_se |
Elektronische Aufsätze |
author-letter |
Vittorio Fusco |
doi_str_mv |
10.3390/dj6030042 |
author2-role |
verfasserin |
title_sort |
osteonecrosis of the jaw in myeloma patients receiving denosumab or zoledronic acid. comment on pivotal trial by raje et al. published on lancet oncology |
callnumber |
RK1-715 |
title_auth |
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology |
abstract |
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. |
abstractGer |
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. |
abstract_unstemmed |
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3, p 42 |
title_short |
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology |
url |
https://doi.org/10.3390/dj6030042 https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e http://www.mdpi.com/2304-6767/6/3/42 https://doaj.org/toc/2304-6767 |
remote_bool |
true |
author2 |
Giuseppina Campisi Paul de Boissieu Federico Monaco Anna Baraldi Gianmauro Numico Alberto Bedogni |
author2Str |
Giuseppina Campisi Paul de Boissieu Federico Monaco Anna Baraldi Gianmauro Numico Alberto Bedogni |
ppnlink |
726120650 |
callnumber-subject |
RK - Dentistry |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/dj6030042 |
callnumber-a |
RK1-715 |
up_date |
2024-07-04T00:08:03.184Z |
_version_ |
1803604913747394560 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029722985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307140515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/dj6030042</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029722985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vittorio Fusco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medication-related osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MRONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple myeloma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">denosumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">zoledronic acid</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppina Campisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul de Boissieu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federico Monaco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Baraldi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianmauro Numico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Bedogni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Dentistry Journal</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">6(2018), 3, p 42</subfield><subfield code="w">(DE-627)726120650</subfield><subfield code="w">(DE-600)2681351-8</subfield><subfield code="x">23046767</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3, p 42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/dj6030042</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.mdpi.com/2304-6767/6/3/42</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2304-6767</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2018</subfield><subfield code="e">3, p 42</subfield></datafield></record></collection>
|
score |
7.3998413 |